{"prompt": "['2016N293064_00', 'CONFIDENTIAL', '2018N394263_00', '205864', 'mild to moderate airflow obstruction identified from the COPDGene cohort. Study', 'participants will continue with their standard of care inhaled medications (i.e. long acting', 'bronchodilators with or without inhaled corticosteroids) while receiving study treatment.', 'Specifically, this study aims to assess whether or not danirixin has the potential to impact', 'disease progression in participants with a COPD progression score indicating they are', 'likely to decline based on 5 year data from COPDGene and support the conduct of a', 'larger Phase III study for disease progression. In addition to lung function and HRQoL,', 'this study will assess moderate/severe COPD exacerbations, health status (CAT), and', 'rescue medication use.', '3.2.', 'Background', 'COPD is a major cause of disability, morbidity, and mortality, resulting in millions of', 'deaths annually worldwide contributing significantly to health care costs [Mathers, 2006;', 'Lopez-Campos, 2016; Vastava, 2015; GOLD, 2016]. The morbidity and mortality of', 'COPD are continuing to increase and worldwide and, by the year 2020, COPD is', 'expected to be the third leading cause of death and fifth leading cause of disability', '[Mathers, 2006; Lopez-Campos, 2016]. The airflow limitation that characterizes COPD', 'is primarily due to small airways disease and parenchymal destruction associated with an', 'excessive inflammatory response in the lung, mainly caused by cigarette smoking [Celli,', '2004]. COPD is characterized by symptoms of chronic and, in many patients,', 'progressive breathlessness (or dyspnea), cough and sputum production. Many COPD', 'patients also suffer from periodic worsening of their COPD symptoms that is beyond the', 'typical day to day variation [Hurst, 2010]. These episodes of worsening symptoms', '(COPD exacerbations) account for a significant proportion of COPD-related and total', 'health care costs. Despite several available therapies that have been shown to reduce', 'COPD exacerbations and respiratory symptoms, many COPD patients continue to', 'experience a high burden of respiratory symptoms and COPD exacerbations resulting in a', 'continuing unmet medical need [Vestbo, 2016]. Additionally, there is growing', 'recognition that a high percentage of COPD patients with mild airflow limitation as well', 'as smokers with preserved lung function suffer from a high burden of symptoms and', 'COPD exacerbations with a subsequent impact on health status [Woodruff, 2016].', 'Therapies that effectively further reduce COPD exacerbations and improve respiratory', 'symptoms could have a substantial impact on healthcare utilization and most importantly', \"result in an improvement in COPD patients' quality of life.\", 'The Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines for the', 'treatment and management of patients with COPD recommend that the management of', 'current respiratory symptoms and subsequent worsening of symptoms resulting in COPD', 'exacerbations should be an important component of COPD patient management [GOLD,', '2016].', 'Danirixin is being evaluated as an addition to standard of care inhaled therapies (i.e. long', 'acting bronchodilators and long acting bronchodilator/corticosteroid combination', 'therapies) and is targeting those COPD patients that continue to have a burden of', 'respiratory symptoms and COPD exacerbations despite management with currently', 'available COPD treatments.', '12']['2016N293064_00', 'CONFIDENTIAL', '2018N394263_00', '205864', '3.3.', 'Benefit/Risk Assessment', 'More detailed information about the potential benefits and risks of danirixin may be', \"found in the danirixin Investigator's Brochure [GlaxoSmithKline Document Number\", 'YM2010/00163/07].', '13']\n\n###\n\n", "completion": "END"}